FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327892820> ?p ?o ?g. }

• W4327892820 endingPage "10916" @default.
• W4327892820 startingPage "10908" @default.
• W4327892820 abstract "The cytoskeletal protein ezrin is upregulated in many cancer types and is strongly associated with poor patient outcome. While the clinical and prognostic value of ezrin has been previously evaluated in breast cancer, most studies to date have been conducted in smaller cohorts (less than 500 cases) or have focused on specific disease characteristics. The current study is the largest of its kind to evaluate ezrin both at the protein and mRNA levels in early-stage breast cancer patients using the Nottingham (n = 1094) and METABRIC (n = 1980) cohorts, respectively.High expression of ezrin was significantly associated with larger tumour size (p = 0.027), higher tumour grade (p < 0.001), worse Nottingham Prognostic Index prognostic group (p = 0.011) and HER2-positive status (p = 0.001). High ezrin expression was significantly associated with adverse survival of breast cancer patients (p < 0.001) and remained associated with survival in multivariate Cox-regression analysis (p = 0.018, hazard ratio (HR) = 1.343, 95% confidence interval (CI) = 1.051-1.716) when potentially confounding factors were included. High ezrin expression was significantly associated with adverse survival of patients whose tumours were categorised as receptor (oestrogen receptor (ER), progesterone receptor (PgR) or HER2) positive (p < 0.001) in comparison to those categorised as triple-negative breast cancer (p = 0.889). High expression of ezrin mRNA (VIL2) in the METABRIC cohort was also significantly associated with adverse survival of breast cancer patients (p < 0.001).Retrospective analyses show that ezrin is an independent prognostic marker, with higher expression associated with shortened survival in receptor-positive (ER, PgR or HER2) patients. Ezrin expression is associated with more aggressive disease and may have clinical utility as a biomarker of patient prognosis in early-stage breast cancer." @default.
• W4327892820 created "2023-03-21" @default.
• W4327892820 creator A5000005180 @default.
• W4327892820 creator A5009916842 @default.
• W4327892820 creator A5019769567 @default.
• W4327892820 creator A5023596082 @default.
• W4327892820 creator A5028298545 @default.
• W4327892820 creator A5035463544 @default.
• W4327892820 creator A5058755793 @default.
• W4327892820 creator A5065285863 @default.
• W4327892820 creator A5075105813 @default.
• W4327892820 creator A5081370615 @default.
• W4327892820 date "2023-03-20" @default.
• W4327892820 modified "2023-10-12" @default.
• W4327892820 title "A retrospective analysis of ezrin protein and <scp>mRNA</scp> expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor‐positive disease" @default.
• W4327892820 cites W1569082160 @default.
• W4327892820 cites W1996572257 @default.
• W4327892820 cites W2005895632 @default.
• W4327892820 cites W2010475702 @default.
• W4327892820 cites W2021582547 @default.
• W4327892820 cites W2032822630 @default.
• W4327892820 cites W2042015318 @default.
• W4327892820 cites W2079681700 @default.
• W4327892820 cites W2088564784 @default.
• W4327892820 cites W2109341253 @default.
• W4327892820 cites W2130653607 @default.
• W4327892820 cites W2133650808 @default.
• W4327892820 cites W2161535630 @default.
• W4327892820 cites W2187482341 @default.
• W4327892820 cites W2469339417 @default.
• W4327892820 cites W2901845764 @default.
• W4327892820 cites W2916326638 @default.
• W4327892820 cites W2926524124 @default.
• W4327892820 cites W2939218108 @default.
• W4327892820 cites W2970299358 @default.
• W4327892820 cites W2983521996 @default.
• W4327892820 cites W3162671174 @default.
• W4327892820 cites W4214944964 @default.
• W4327892820 cites W4327892820 @default.
• W4327892820 doi "https://doi.org/10.1002/cam4.5802" @default.
• W4327892820 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36938826" @default.
• W4327892820 hasPublicationYear "2023" @default.
• W4327892820 type Work @default.
• W4327892820 citedByCount "1" @default.
• W4327892820 countsByYear W43278928202023 @default.
• W4327892820 crossrefType "journal-article" @default.
• W4327892820 hasAuthorship W4327892820A5000005180 @default.
• W4327892820 hasAuthorship W4327892820A5009916842 @default.
• W4327892820 hasAuthorship W4327892820A5019769567 @default.
• W4327892820 hasAuthorship W4327892820A5023596082 @default.
• W4327892820 hasAuthorship W4327892820A5028298545 @default.
• W4327892820 hasAuthorship W4327892820A5035463544 @default.
• W4327892820 hasAuthorship W4327892820A5058755793 @default.
• W4327892820 hasAuthorship W4327892820A5065285863 @default.
• W4327892820 hasAuthorship W4327892820A5075105813 @default.
• W4327892820 hasAuthorship W4327892820A5081370615 @default.
• W4327892820 hasBestOaLocation W43278928201 @default.
• W4327892820 hasConcept C104317684 @default.
• W4327892820 hasConcept C10515644 @default.
• W4327892820 hasConcept C121608353 @default.
• W4327892820 hasConcept C126322002 @default.
• W4327892820 hasConcept C127561419 @default.
• W4327892820 hasConcept C142669718 @default.
• W4327892820 hasConcept C143998085 @default.
• W4327892820 hasConcept C1491633281 @default.
• W4327892820 hasConcept C167135981 @default.
• W4327892820 hasConcept C207103383 @default.
• W4327892820 hasConcept C2779740036 @default.
• W4327892820 hasConcept C2780246058 @default.
• W4327892820 hasConcept C44249647 @default.
• W4327892820 hasConcept C502942594 @default.
• W4327892820 hasConcept C50382708 @default.
• W4327892820 hasConcept C530470458 @default.
• W4327892820 hasConcept C54355233 @default.
• W4327892820 hasConcept C55493867 @default.
• W4327892820 hasConcept C71924100 @default.
• W4327892820 hasConcept C86803240 @default.
• W4327892820 hasConceptScore W4327892820C104317684 @default.
• W4327892820 hasConceptScore W4327892820C10515644 @default.
• W4327892820 hasConceptScore W4327892820C121608353 @default.
• W4327892820 hasConceptScore W4327892820C126322002 @default.
• W4327892820 hasConceptScore W4327892820C127561419 @default.
• W4327892820 hasConceptScore W4327892820C142669718 @default.
• W4327892820 hasConceptScore W4327892820C143998085 @default.
• W4327892820 hasConceptScore W4327892820C1491633281 @default.
• W4327892820 hasConceptScore W4327892820C167135981 @default.
• W4327892820 hasConceptScore W4327892820C207103383 @default.
• W4327892820 hasConceptScore W4327892820C2779740036 @default.
• W4327892820 hasConceptScore W4327892820C2780246058 @default.
• W4327892820 hasConceptScore W4327892820C44249647 @default.
• W4327892820 hasConceptScore W4327892820C502942594 @default.
• W4327892820 hasConceptScore W4327892820C50382708 @default.
• W4327892820 hasConceptScore W4327892820C530470458 @default.
• W4327892820 hasConceptScore W4327892820C54355233 @default.
• W4327892820 hasConceptScore W4327892820C55493867 @default.
• W4327892820 hasConceptScore W4327892820C71924100 @default.
• W4327892820 hasConceptScore W4327892820C86803240 @default.
• W4327892820 hasFunder F4320313290 @default.

• next